Having established that blocking the B1R and B2R signalling slows CRC tumor progression and that CRC tumor cells express bradykinin receptors we wanted to know if receptor activation or blockade modulate tumor cell characteristics directly. This evidence concerns the gene BDKRB2 and colorectal carcinoma.